The pace of internationalization of pharmaceutical machinery companies is also accelerating as local innovative pharmaceutical companies go abroad to speed up

In recent years, driven by various factors such as policies, technology, and capital markets, China's innovative drug industry has begun to develop rapidly
.
The enthusiasm for innovation of local pharmaceutical companies is high, R&D investment is continuously increasing, and the number of approved new drugs is also showing a continuous growth trend
.
It is worth noting that as more and more pharmaceutical companies join the innovation track, competition among pharmaceutical companies has also become increasingly fierce
.
The pace of internationalization of pharmaceutical machinery companies is accelerating (Image source: Pharmaceutical Network) Local pharmaceutical companies are accelerating the export of innovative drugs in order to cope with the increasing competition in the pharmaceutical market, the pressure of price cuts brought by domestic centralized procurement, and the return space of innovative drugs after the market Constantly being squeezed and other circumstances, some capable local innovative pharmaceutical companies have begun to accelerate their "going abroad
.
" According to statistics, since Microchip Technology authorized Chidamide to US HUYA at a price of tens of millions of US dollars in 2007, the wave of innovative pharmaceutical companies has continued to emerge, and since 2021, the trend has continued.
Up to now, local pharmaceutical companies have The number of overseas authorized transactions has exceeded 30, involving a large number of pharmaceutical companies such as BeiGene, Rongchang Biotechnology, and Livzon Group
.
In addition to the continuous increase in the number of drugs going overseas, judging from the value of a single transaction this year, the transaction value during the year has also reached a new high
.
It is reported that Rongchang Biotech is authorized to go to sea with a higher amount this year
.
On August 8, 2021, Rongchang Biotechnology and Seattle Genetics reached a cooperation agreement to develop and commercialize its new ADC drug, vedicitumumab.
The transaction amount was as high as US$2.
6 billion
.
At present, with the continuous improvement of innovation strength, a large number of pharmaceutical companies are still accelerating the process of going overseas
.
On November 23, BeiGene announced that it had completed the acquisition of land in the Princeton West Innovation Park in Hopewell, New Jersey, USA, for the construction of an innovative drug production base covering an area of ​​42 acres (about 170,000 square meters)
.
After the completion of the base, it will further expand and enrich the company's global supply chain, and build new production capacity for the company's deep biopharmaceutical product pipeline and drug candidates
.
The internationalization of pharmaceutical machinery companies is also accelerating.
On the whole, internationalization has become a major trend in the development of domestic innovative pharmaceutical companies.

.
In fact, in the context of severe homogeneity of products in the domestic equipment market and increasingly fierce market competition, pharmaceutical machinery companies are also accelerating the development of overseas markets and formulating international strategies in order to seek new growth points
.
It is reported that under the international layout, many pharmaceutical companies have achieved new growth in performance
.
For example, Chutian Technology's 2020 annual report shows that last year's operating income was 3.
576 billion yuan, a year-on-year increase of 13.
88%
.
Among them, overseas performance achieved steady growth, with a year-on-year increase of 6.
63%
.
It is worth mentioning that the current pace of internationalization of domestic pharmaceutical equipment companies is accelerating
.
Many companies have put forward new visions in terms of internationalization
.
For example, Chutian Technology stated in an agency survey in July that in the next 3-5 years, the company plans to maintain an annual increase of 10%-20% in its export business.
It is planned that the export business income of Chutian headquarters will account for the total revenue by about 2025.
40%-50%
of In addition, Liaoning Chunguang also publicly stated in 2019 that it has begun to establish a trading company in North America and will conduct online sales and purchase of products through the US Torras e-commerce platform
.
With the help of the combination of entity and network, Liaoning Chunguang will have a more long-term development in the future
.
It is worth mentioning that, according to the short-term development goals set by Liaoning Chunguang at that time, by 2025, when the company's vision and planning are fully realized, it will strive to account for 50% of both international sales and domestic sales, and achieve both larger and larger Strong situation
.
Conclusion From the overall point of view, in terms of the internationalization strategy, local pharmaceutical companies and pharmaceutical machinery companies are continuing to deepen their cultivation, and continue to increase the proportion of export business revenue in total business revenue
.
It is expected that with the efforts of these companies in the future, more and more domestically-made innovative drugs and pharmaceutical equipment will compete in the international market.
While continuously gaining recognition in overseas markets, they will also further enhance the influence of Chinese pharmaceutical products
.